Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Harvard Business School
Dow
AstraZeneca

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Serlopitant


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Serlopitant?

Serlopitant is an investigational drug.

There have been 12 clinical trials for Serlopitant. The most recent clinical trial was a Phase 3 trial, which was initiated on May 2nd 2018.

The most common disease conditions in clinical trials are Pruritus, Prurigo, and Neurodermatitis. The leading clinical trial sponsors are Menlo Therapeutics Inc., Vyne Therapeutics Inc., and Epidermolysis Bullosa Research Partnership.

There are twenty-five US patents protecting this investigational drug and ninety-nine international patents.

Recent Clinical Trials for Serlopitant
TitleSponsorPhase
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaEpidermolysis Bullosa Research PartnershipPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaMenlo TherapeuticsPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaStanford UniversityPhase 2

See all Serlopitant clinical trials

Clinical Trial Summary for Serlopitant

Top disease conditions for Serlopitant
Top clinical trial sponsors for Serlopitant

See all Serlopitant clinical trials

US Patents for Serlopitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Serlopitant ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Serlopitant ⤷  Try it Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Serlopitant ⤷  Try it Free ⤷  Try it Free
Serlopitant ⤷  Try it Free Use of NK-1 receptor antagonist serlopitant in pruritus Menlo Therapeutics Inc. (Redwood, CA) ⤷  Try it Free
Serlopitant ⤷  Try it Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Serlopitant ⤷  Try it Free Use of NK-1 receptor antagonist serlopitant in pruritus MENLO THERAPEUTICS INC. (Redwood City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Serlopitant

Drugname Country Document Number Estimated Expiration Related US Patent
Serlopitant Australia AU2017261372 2036-05-05 ⤷  Try it Free
Serlopitant Canada CA3023278 2036-05-05 ⤷  Try it Free
Serlopitant China CN107847398 2036-05-05 ⤷  Try it Free
Serlopitant European Patent Office EP3452003 2036-05-05 ⤷  Try it Free
Serlopitant Hong Kong HK1249728 2036-05-05 ⤷  Try it Free
Serlopitant Japan JP2019520866 2036-05-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Harvard Business School
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.